Top

Published in:

Open Access 01-12-2012 | Review

Therapy for metastatic melanoma: the past, present, and future

Authors: Laura Finn, Svetomir N Markovic, Richard W Joseph

Published in: BMC Medicine | Issue 1/2012

Abstract

Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.

Available only for authorised users

Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA: Cancer Journal for Clinicians. 2010, 60: 277-300. 10.3322/caac.20073.

Hill G, Krementz E, Hill H: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer. 1984, 53: 1299-1305. 10.1002/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4.CrossRefPubMed

Atkins M, Lotze M, Dutcher J, Fisher R: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology. 1999, 17 (7): 2105-2116.PubMed

Phan G, Attia P, Steinberg S, White D: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of Clinical Oncology. 2001, 19 (15): 3477-3482.PubMed

Davies H, Bignell G, Cox C, Stephens P: Mutations of the BRAF gene in human cancer. Nature. 2002, 417.

Curtin J, Fridyland J, Kageshita T, Patel H: Distinct sets of genetic alterations in melanoma. New England Journal of Medicine. 2005, 353 (20): 2135-2147. 10.1056/NEJMoa050092.CrossRefPubMed

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J: Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. European journal of cancer. 2011

Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, et al: Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. Cancer. 2011

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004, 64 (19): 7099-7109. 10.1158/0008-5472.CAN-04-1443.CrossRefPubMed

10.

Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, et al: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006, 95 (5): 581-586. 10.1038/sj.bjc.6603291.CrossRefPubMedPubMedCentral

11.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, et al: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008, 26 (13): 2178-2185. 10.1200/JCO.2007.14.8288.CrossRef

12.

Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, et al: Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. J Clin Oncol. 2009, 27 (17): 2823-2830. 10.1200/JCO.2007.15.7636.CrossRefPubMed

13.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al: Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine. 2010, 363 (9): 809-819. 10.1056/NEJMoa1002011.CrossRefPubMedPubMedCentral

14.

Smalley K, Sondak V: Melanoma-an unlikely poster child for personalized cancer therapy. New England Journal of Medicine. 2010, 363 (9).

15.

Ribas A, Kim K, Schuchter L, Gonzalez A: BRIM-2: an open label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Journal of CLinical Oncology, 2011 ASCO Annual Meeting Proceedings. 2011, 29 (15s): 8509.

16.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011, 364 (26): 2507-2516. 10.1056/NEJMoa1103782.CrossRefPubMedPubMedCentral

17.

Kefford R, Arkenau H, Brown M, Millward M: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of CLinical Oncology, 2010 ASCO Annual Meeting Proceedings. 2010, 28 (15s): 8503.

18.

Menzies LV, Chatfield MS, Carlino JR, Howle RA, Scolyer JF, Thompson RF, Kefford GV, Long : BRAF mutation by age-decade and body mass index in metastatic melanoma. Journal of Clinical Oncology. 2011, 29: 2011 (suppl; abstr 8507)

19.

Long KR, Carr PJA, et al: Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets). Ann Oncol. 2010, 21: LBA27 [abstr]

20.

Dummer JR, Goldinger SM, Wagner I, Mitchell L, Veronese ML, Nick S, Hilfiker P, Gobbi S: An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol. 2011, 29: (suppl; abstr 8548) 2011

21.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al: RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. New England Journal of Medicine. 2012, 366 (3): 207-215. 10.1056/NEJMoa1105358.CrossRefPubMedPubMedCentral

22.

Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nature reviews Cancer. 2007, 7 (2): 95-106. 10.1038/nrc2051.CrossRefPubMed

23.

Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine. 2011, 364 (26): 2517-2526. 10.1056/NEJMoa1104621.CrossRefPubMed

24.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010, 363 (8): 711-723. 10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentral

25.

Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, MacConaill LE, Hahn WC, et al: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. Journal of Clinical Oncology. 2011, 29 (22): 3085-3096. 10.1200/JCO.2010.33.2312.CrossRefPubMedPubMedCentral

26.

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293 (5531): 876-880. 10.1126/science.1062538.CrossRefPubMed

27.

Ellis LM, Hicklin DJ: Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res. 2009, 15 (24): 7471-7478. 10.1158/1078-0432.CCR-09-1070.CrossRefPubMed

28.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010, 468 (7326): 973-977. 10.1038/nature09626.CrossRefPubMedPubMedCentral

29.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010, 468 (7326): 968-972. 10.1038/nature09627.CrossRefPubMedPubMedCentral

30.

Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008, 68 (12): 4853-4861. 10.1158/0008-5472.CAN-07-6787.CrossRefPubMedPubMedCentral

31.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010, 18 (6): 683-695. 10.1016/j.ccr.2010.11.023.CrossRefPubMedPubMedCentral

32.

Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010, 17 (1): 77-88. 10.1016/j.ccr.2009.11.022.CrossRefPubMedPubMedCentral

33.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007, 316 (5827): 1039-1043. 10.1126/science.1141478.CrossRefPubMed

34.

Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, et al: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008, 118 (7): 2609-2619.PubMedPubMedCentral

35.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011, 71 (7): 2750-2760. 10.1158/0008-5472.CAN-10-2954.CrossRefPubMedPubMedCentral

36.

Infante JR, Falchook GS, Lawrence DP, Weber JS: Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 dosed in combination with oral BRAF inhibitor. Journal of CLinical Oncology, 2011 ASCO Annual Meeting Proceedings. 2011, 29 (18s).

37.

Jackson GW, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Bao Y, Shahabi V: Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. J Clin Oncol. 2011, 29: 2011 (suppl; abstr 2587)

38.

Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, et al: Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA. 2009, 106 (8): 2729-2734. 10.1073/pnas.0813175106.CrossRefPubMedPubMedCentral

39.

Fu T, He Q, Sharma P: The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer research. 2011, 71 (16): 5445-5454. 10.1158/0008-5472.CAN-11-1138.CrossRefPubMed

40.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011, 29 (3): 489-498. 10.1007/s10637-009-9376-8.CrossRefPubMed

41.

Patel SP, Bedikian AY, Papadopoulos NE, Hwu W, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi LG, Woodard K, et al: Ipilimumab plus temozolomide in metastatic melanoma. ASCO Meeting Abstracts. 2011, 29 (15_suppl): 8579.

42.

Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, et al: A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. ASCO Meeting Abstracts. 2011, 29 (15_suppl): 8511.

43.

ClinicalTrials.gov. [http://www.clinicaltrials.gov]

44.

Lord J, Hackman R, Moklebust A, Thompson J, Higano C, Chielens D, Steinbach G, McDonald G: Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3<sup>+</sup> T Cells. Dig Dis Sci. 2010, 55 (5): 1396-1405. 10.1007/s10620-009-0839-8.CrossRefPubMed

45.

Curtin JA, Busam K, Pinkel D, Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006, 24 (26): 4340-4346. 10.1200/JCO.2006.06.2984.CrossRefPubMed

46.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279 (5350): 577-580. 10.1126/science.279.5350.577.CrossRefPubMed

47.

Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol. 2001, 193 (4): 505-510. 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E.CrossRefPubMed

48.

Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, et al: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 1995, 85 (3): 790-798.PubMed

49.

Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K, Inokuchi K: Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2011, 25 (9): 1423-1432. 10.1038/leu.2011.104.CrossRefPubMed

50.

Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, et al: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009, 8 (8): 2079-2085. 10.1158/1535-7163.MCT-09-0459.CrossRefPubMedPubMedCentral

51.

Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, et al: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008, 14 (21): 6821-6828. 10.1158/1078-0432.CCR-08-0575.CrossRefPubMed

52.

Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008, 99 (5): 734-740. 10.1038/sj.bjc.6604482.CrossRefPubMedPubMedCentral

53.

Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011, 29 (21): 2904-2909. 10.1200/JCO.2010.33.9275.CrossRef

54.

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al: KIT as a therapeutic target in metastatic melanoma. JAMA: the journal of the American Medical Association. 2011, 305 (22): 2327-2334. 10.1001/jama.2011.746.CrossRefPubMed

55.

Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M: A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011, 117 (10): 2202-2208. 10.1002/cncr.25766.CrossRefPubMed

56.

Riese DJ, Gallo RM, Settleman J: Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays. 2007, 29 (6): 558-565. 10.1002/bies.20582.CrossRefPubMedPubMedCentral

57.

Frey MR, Edelblum KL, Mullane MT, Liang D, Polk DB: The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology. 2009, 136 (1): 217-226. 10.1053/j.gastro.2008.09.023.CrossRefPubMed

58.

Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009, 41 (10): 1127-1132. 10.1038/ng.438.CrossRefPubMedPubMedCentral

59.

Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ, Fabra A: Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004, 123 (6): 1151-1161. 10.1111/j.0022-202X.2004.23460.x.CrossRefPubMed

60.

Srivastava A, Ralhan R, Kaur J: Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech. 2003, 60 (2): 208-224. 10.1002/jemt.10259.CrossRefPubMed

61.

Perez DG, Suman VJ, Fitch TR, Amatruda T, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009, 115 (1): 119-127. 10.1002/cncr.23987.CrossRefPubMedPubMedCentral

62.

Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, et al: BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012, 30 (1): 34-41. 10.1200/JCO.2011.34.6270.CrossRef

63.

Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN: A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011, 117 (8): 1704-1710. 10.1002/cncr.25659.CrossRefPubMed

64.

Fruehauf JP, Lutzky J, McDermott DF, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, et al: Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, 3, in Patients with Metastatic Melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011

65.

Hong DS, Koetz BS, Kurzrock R, Senzer NN, Hanekom W, Naing A, Wheler JJ, Mink J, Ren M, Nemunaitis JJ: Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. ASCO Meeting Abstracts. 2010, 28 (15_suppl): 2540.

66.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26: 677-704. 10.1146/annurev.immunol.26.021607.090331.CrossRefPubMed

67.

Riley JL: PD-1 signaling in primary T cells. Immunol Rev. 2009, 229 (1): 114-125. 10.1111/j.1600-065X.2009.00767.x.CrossRefPubMedPubMedCentral

68.

Okazaki T, Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006, 27 (4): 195-201. 10.1016/j.it.2006.02.001.CrossRefPubMed

69.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010, 28 (19): 3167-3175. 10.1200/JCO.2009.26.7609.CrossRefPubMedPubMedCentral

70.

Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988, 319 (25): 1676-1680. 10.1056/NEJM198812223192527.CrossRefPubMed

71.

Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994, 86 (15): 1159-1166. 10.1093/jnci/86.15.1159.CrossRefPubMed

72.

Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004, 101 (Suppl 2): 14639-14645.CrossRefPubMedPubMedCentral

73.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005, 23 (10): 2346-2357. 10.1200/JCO.2005.00.240.CrossRefPubMedPubMedCentral

74.

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011, 17 (13): 4550-4557. 10.1158/1078-0432.CCR-11-0116.CrossRefPubMedPubMedCentral

75.

Dudley ME: Adoptive cell therapy for patients with melanoma. J Cancer. 2011, 2: 360-362.CrossRefPubMedPubMedCentral

76.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, et al: Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011, 17 (14): 4882-4891. 10.1158/1078-0432.CCR-10-2769.CrossRefPubMedPubMedCentral

77.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006, 314 (5796): 126-129. 10.1126/science.1129003.CrossRefPubMedPubMedCentral

78.

Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, et al: Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. Journal of Immunotherapy. 2012, 35 (1): 66-72. 10.1097/CJI.0b013e3182372636.CrossRefPubMedPubMedCentral

79.

Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, et al: Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009, 27 (16): 2645-2652. 10.1200/JCO.2008.19.1106.CrossRefPubMedPubMedCentral

80.

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011, 364 (22): 2119-2127. 10.1056/NEJMoa1012863.CrossRefPubMedPubMedCentral

81.

Joseph RW, Hwu P, Davies MA, Atkins MB, Sullivan RJ: Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2. ASCO Meeting Abstracts. 2011, 29 (15_suppl): 8537.

82.

Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer research. 2010, 70 (13): 5213-5219. 10.1158/0008-5472.CAN-10-0118.CrossRefPubMed

83.

Allen PJ, Coit DG: The surgical management of metastatic melanoma. Ann Surg Oncol. 2002, 9 (8): 762-770. 10.1007/BF02574498.CrossRefPubMed

84.

Meyer T, Merkel S, Goehl J, Hohenberger W: Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000, 89 (9): 1983-1991. 10.1002/1097-0142(20001101)89:9<1983::AID-CNCR15>3.3.CO;2-J.CrossRefPubMed

85.

Leo F, Cagini L, Rocmans P, Cappello M, Geel AN, Maggi G, Goldstraw P, Pastorino U: Lung metastases from melanoma: when is surgical treatment warranted?. Br J Cancer. 2000, 83 (5): 569-572. 10.1054/bjoc.2000.1335.CrossRefPubMedPubMedCentral

86.

Herman P, Machado MA, Montagnini AL, D'Albuquerque LA, Saad WA, Machado MC: Selected patients with metastatic melanoma may benefit from liver resection. World J Surg. 2007, 31 (1): 171-174. 10.1007/s00268-006-0375-z.CrossRefPubMed

87.

Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL: Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001, 136 (8): 950-955. 10.1001/archsurg.136.8.950.CrossRefPubMed

88.

Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK: A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/23/prepub

Title: Therapy for metastatic melanoma: the past, present, and future
Authors: Laura Finn
Svetomir N Markovic
Richard W Joseph
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2012
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-10-23

At a glance: The STEP trials

Springer Medicine

Therapy for metastatic melanoma: the past, present, and future

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis

New race and ethnicity standards: elucidating health disparities in diabetes

A tool to facilitate clinical biomarker studies - a tissue dictionary based on the Human Protein Atlas

Prevalence and prognosis of non-specific chest pain among patients hospitalized for suspected acute coronary syndrome - a systematic literature search

Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3)

Back to past leeches: repeated phlebotomies and cardiovascular risk